Kathryn Guarini - 30 Oct 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 16:22:37 UTC
Prior SEC filing
03 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kathryn Guarini
Filing notes and source

Key filing fact

Kathryn Guarini filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 03 Nov 2026.

Key facts

  • This page summarizes Kathryn Guarini's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 03 Nov 2026, 16:22.

Change

  • Previous filing in this sequence was filed on 03 Sep 2026.
  • Current net transaction value: -$360,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001992352 Primary reporting owner

Guarini Kathryn

Relationship
Director
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature
/s/ Kathryn Guarini
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Options Exercise

Transaction value
Shares
+400
Change %
+66%
Price
$719.37*
Shares after
1,003
Date
30 Oct 2026
Ownership
Direct
Footnotes
F1
REGN transaction

Common Stock

Sale

Transaction value
-$360,000
Shares
-400
Change %
-40%
Price
$900.00
Shares after
603
Date
30 Oct 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-400
Change %
-35%
Price
$0.000000*
Shares after
758
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
400
Exercise price
$719.37
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.

Footnote F2

On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .